XPO1 and leukemia: Given that inhibiting binding of Crm1 to NES cargo also impairs the interaction of Crm1 with NUP98 fusion proteins [20], SINEs could likewise be of therapeutic utility in the context of NUP98 fusion leukemias, which respond poorly to existing therapies.